A novel yeast-derived aldehyde-reducing compound MF001 protects against alcohol-induced liver damage
PLOS One · 2025
DOI: 10.1371/journal.pone.0327648 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Eun-Ho Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Keimyung University School of Medicine, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Saccharomyces cerevisiae, Aldehydes, Protective Agents, Fatty Liver, Alcoholic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, South Korea, Ministry of SMEs and Startups.
Abstract (Originalsprache)
Alcohol-induced fatty liver disease is a significant contributor to global mortality, primarily resulting from excessive alcohol consumption and subsequent hepatic damage. This study investigated the therapeutic potential of MF001, an aldehyde-reducing compound derived from the yeast Saccharomyces cerevisiae in alcohol-induced liver damage. Using a Lieber-DeCarli ethanol diet-induced live disease model, we assessed the effects of MF001 on lipogenesis, oxidative stress, and inflammation. MF001 treatment significantly reduced lipid accumulation, as indicated by decreased expression of lipogenic genes. Moreover, MF001 suppresses reactive oxygen species (ROS) production indicated by reduced malondialdehyde levels and ROS-associated inflammatory markers, including Tnf-α, Il-6, and Mcp-1. Histological analysis revealed decreased hepatic lipid deposition and inflammation following MF001 administration. Furthermore, MF001 modulated alcohol metabolism by downregulating Cyp2e1 and Adh1, thereby decreasing acetaldehyde accumulation and improving liver function, as evidenced by normalized ALT and AST levels. Our findings suggest that MF001 alleviates alcohol-induced liver damage through its anti-inflammatory, antioxidant, and lipid-lowering properties, highlighting its potential as a function agent for preventing and treating alcohol-induced fatty liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Keimyung University School of Medicine, Daegu, Republic of Korea.
- Department of Physiology, College of Medicine and Institute of Medical Sciences, Gyeongsang National University, Jinju, Korea.
- Picoentech Co., Ltd., Gyeong gi-do, Republic of Korea.
- Department of Biomedical Science & Systems Biology, Dankook University, Cheonan, Republic of Korea.
ORCID-Profile: Sulagna Mukherjee, Hung Taeck Kwon, Seung-Soon Im
Förderung
- Ministry of Science and ICT, South Korea
- Ministry of SMEs and Startups
Zitieren
APA
Lee, E. H., Seo, M. H., Park, S. Y., Mukherjee, S., Lee, J. H., Kang, S., Lee, J. Y., Lee, N., Kwon, H. T., & Im, S. S. (2025). A novel yeast-derived aldehyde-reducing compound MF001 protects against alcohol-induced liver damage. PLOS One. https://doi.org/10.1371/journal.pone.0327648
Vancouver
Lee EH, Seo MH, Park SY, Mukherjee S, Lee JH, Kang S, et al. A novel yeast-derived aldehyde-reducing compound MF001 protects against alcohol-induced liver damage. PLOS One. 2025. doi:10.1371/journal.pone.0327648
BibTeX
@article{Lee2025,
author = {Lee, Eun-Ho and Seo, Min-Hee and Park, Soo-Young and Mukherjee, Sulagna and Lee, Jae-Ho and Kang, Sora and Lee, Ji-Yu and Lee, Namgyu and Kwon, Hung Taeck and Im, Seung-Soon},
title = {A novel yeast-derived aldehyde-reducing compound MF001 protects against alcohol-induced liver damage},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0327648}
}
EUVIMED